- Home
- OMI vs ETNB Comparison
OMI vs ETNB Comparison
Compare OMI & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMI
- ETNB
- Stock Information
- Founded
- OMI 1882
- ETNB 2018
- Country
- OMI United States
- ETNB United States
- Employees
- OMI N/A
- ETNB N/A
- Industry
- OMI Medical Specialities
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- OMI Health Care
- ETNB Health Care
- Exchange
- OMI Nasdaq
- ETNB Nasdaq
- Market Cap
- OMI 909.7M
- ETNB 867.4M
- IPO Year
- OMI N/A
- ETNB 2019
- Fundamental
- Price
- OMI $12.25
- ETNB $7.93
- Analyst Decision
- OMI Buy
- ETNB Buy
- Analyst Count
- OMI 6
- ETNB 7
- Target Price
- OMI $19.58
- ETNB $30.33
- AVG Volume (30 Days)
- OMI 902.0K
- ETNB 901.8K
- Earning Date
- OMI 11-04-2024
- ETNB 11-07-2024
- Dividend Yield
- OMI N/A
- ETNB N/A
- EPS Growth
- OMI N/A
- ETNB N/A
- EPS
- OMI N/A
- ETNB N/A
- Revenue
- OMI $10,660,960,000.00
- ETNB N/A
- Revenue This Year
- OMI $4.87
- ETNB N/A
- Revenue Next Year
- OMI $4.01
- ETNB $133.30
- P/E Ratio
- OMI N/A
- ETNB N/A
- Revenue Growth
- OMI 4.22
- ETNB N/A
- 52 Week Low
- OMI $11.42
- ETNB $7.00
- 52 Week High
- OMI $28.35
- ETNB $16.63
- Technical
- Relative Strength Index (RSI)
- OMI 41.61
- ETNB 42.09
- Support Level
- OMI $11.98
- ETNB $9.00
- Resistance Level
- OMI $13.56
- ETNB $10.01
- Average True Range (ATR)
- OMI 0.71
- ETNB 0.80
- MACD
- OMI -0.01
- ETNB -0.10
- Stochastic Oscillator
- OMI 35.78
- ETNB 8.52
About OMI Owens & Minor Inc.
Owens & Minor Inc distributes consumable medical supplies to a variety of providers. The business is under two segments: Products & Healthcare Services and Patient Direct. The Products & Healthcare Services segment manufactures and sources medical surgical products through its production and kitting operations and provides medical supplies and solutions for the prevention of healthcare-associated infections across the acute and alternate site channels. The Patient Direct segment provides delivery of disposable medical supplies sold directly to patients and home health agencies. Majority of the revenue is generated from Products & Healthcare Services segment.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).